ClariClariTrial
SearchBoston hubTechnology

Targeted protein degradation (TPD)

TPD is a major modality in the Boston cluster: induced proximity, E3 recruitment, and catalytic removal of disease proteins including difficult transcription factors.

What it is

  • Bifunctional small molecules (often called PROTACs) or glues that bring a target protein and an E3 ligase into proximity, leading to ubiquitination and proteasomal degradation.
  • Molecular glues can stabilize protein-protein interfaces without classic PROTAC architecture.
  • The modality is a defining theme for several Kendall and Watertown TPD companies and shows up in competitive and target pages across Clari.

Boston and Cambridge context

Ecosystem context appears in the competitive landscape page, in meeting and agent prompts (Greater Boston TPD), and in deep company case studies. Use registry-backed trials to verify which sponsors list which programs.

Related target biology

Example case studies

Internal links

Keywords: PROTAC, molecular glue, E3 ligase, induced proximity, degrader. Curated for Clari; not medical, legal, or investment advice. Compare with public registries and company disclosures.